MYRIAD GENETICS INC (MYGN)
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical